Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CHARM-03: A Randomized, Open Label, Crossover Phase 1 Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel Administered Rectally and Vaginally to HIV-1 Seronegative Adults

NCT02346084 is registered in ClinicalTrials.gov with International Partnership for Microbicides, Inc. as lead sponsor.

NCT NCT02346084
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02346084 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CHARM-03: A Randomized, Open Label, Crossover Phase 1 Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel Administered Rectally and Vaginally to HIV-1 Seronegative Adults
Lead sponsor
International Partnership for Microbicides, Inc.
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2015
Completion date
March 31, 2016
Enrollment
19 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv/aids